Gnubiotics Sciences SA a Swiss biotech company pioneering novel microbiome targeted solutions for humans and companion animals recently announced the allowance from the European Patent Office (EPO) for its patent application 19812838.1 (EPO publication 3695018). Yemi Adesokan at Gnubiotics SA explains how this is a key patent filing covering the microbiomebased prediction, identification, and treatment of feline obesity.